Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Modeling the conformations of Neisseria meningitidis serogroup a CPS and a carba-analogue: Implications for vaccine development.

Hlozek J, Ravenscroft N, Kuttel MM.

Carbohydr Res. 2019 Dec 1;486:107838. doi: 10.1016/j.carres.2019.107838. Epub 2019 Oct 16.

PMID:
31654945
2.

Use of NMR as an analytical tool in the process development of conjugate vaccines against Haemophilus influenzae type b (Hib) and meningococcal serogroup A (MenA).

Beri S, Gandhi D, Ravenscroft N.

Biologicals. 2019 Nov;62:102-106. doi: 10.1016/j.biologicals.2019.10.005. Epub 2019 Oct 20.

PMID:
31645306
3.

A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.

Akher FB, Farrokhzadeh A, Ravenscroft N, Kuttel MM.

Biochemistry. 2019 Oct 15;58(41):4246-4259. doi: 10.1021/acs.biochem.9b00710. Epub 2019 Oct 7.

PMID:
31589411
4.

Characterization of the Salmonella Typhimurium core oligosaccharide and its reducing end 3-deoxy-d-manno-oct-2-ulosonic acid used for conjugate vaccine production.

De Benedetto G, Micoli F, Londero S, Salvini L, Sturiale L, Garozzo D, Ravenscroft N, Giannelli C, Cescutti P.

Carbohydr Res. 2019 Jul 15;481:43-51. doi: 10.1016/j.carres.2019.05.014. Epub 2019 Jun 6.

PMID:
31228656
5.

Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate.

Ravenscroft N, Braun M, Schneider J, Dreyer AM, Wetter M, Haeuptle MA, Kemmler S, Steffen M, Sirena D, Herwig S, Carranza P, Jones C, Pollard AJ, Wacker M, Kowarik M.

Glycobiology. 2019 Aug 20;29(9):669-680. doi: 10.1093/glycob/cwz044.

6.

Theoretical and laboratory investigations of the effects of hydroxyproline ingestion on the metabolic and physicochemical risk factors for calcium oxalate kidney stone formation in a small group of healthy subjects.

Rodgers A, Cele P, Ravenscroft N, Edmonds-Smith C, Jackson G.

Int Urol Nephrol. 2019 Jul;51(7):1121-1127. doi: 10.1007/s11255-019-02186-2. Epub 2019 Jun 3.

PMID:
31161522
7.

O-acetylation of typhoid capsular polysaccharide confers polysaccharide rigidity and immunodominance by masking additional epitopes.

Hitri K, Kuttel MM, De Benedetto G, Lockyer K, Gao F, Hansal P, Rudd TR, Beamish E, Rijpkema S, Ravenscroft N, Bolgiano B.

Vaccine. 2019 Jun 27;37(29):3866-3875. doi: 10.1016/j.vaccine.2019.05.050. Epub 2019 May 31.

PMID:
31160100
8.

Structure of the capsular polysaccharide of the KPC-2-producing Klebsiella pneumoniae strain KK207-2 and assignment of the glycosyltransferases functions.

Bellich B, Ravenscroft N, Rizzo R, Lagatolla C, D'Andrea MM, Rossolini GM, Cescutti P.

Int J Biol Macromol. 2019 Jun 1;130:536-544. doi: 10.1016/j.ijbiomac.2019.02.128. Epub 2019 Feb 22.

PMID:
30802520
9.

Conformation and Cross-Protection in Group B Streptococcus Serotype III and Streptococcus pneumoniae Serotype 14: A Molecular Modeling Study.

Kuttel MM, Ravenscroft N.

Pharmaceuticals (Basel). 2019 Feb 13;12(1). pii: E28. doi: 10.3390/ph12010028.

10.

Conformations of Neisseria meningitidis serogroup A and X polysaccharides: The effects of chain length and O-acetylation.

Hlozek J, Kuttel MM, Ravenscroft N.

Carbohydr Res. 2018 Jul 30;465:44-51. doi: 10.1016/j.carres.2018.06.007. Epub 2018 Jun 22.

PMID:
29940397
11.

Genetic and structural elucidation of capsular polysaccharides from Streptococcus pneumoniae serotype 23A and 23B, and comparison to serotype 23F.

Ravenscroft N, Omar A, Hlozek J, Edmonds-Smith C, Follador R, Serventi F, Lipowsky G, Kuttel MM, Cescutti P, Faridmoayer A.

Carbohydr Res. 2017 Oct 10;450:19-29. doi: 10.1016/j.carres.2017.08.006. Epub 2017 Aug 18.

PMID:
28837839
12.

Cross-protection in Neisseria meningitidis serogroups Y and W polysaccharides: A comparative conformational analysis.

Kuttel MM, Timol Z, Ravenscroft N.

Carbohydr Res. 2017 Jun 29;446-447:40-47. doi: 10.1016/j.carres.2017.05.004. Epub 2017 May 10.

PMID:
28501716
13.

Correction to Complete Structural Elucidation of an Oxidized Polysialic Acid Drug Intermediate by Nuclear Magnetic Resonance Spectroscopy.

Ray GJ, Ravenscroft N, Siekmann J, Zhang Z, Sanders P, Shaligram U, Szabo CM, Kosma P.

Bioconjug Chem. 2016 Aug 17;27(8):1958. doi: 10.1021/acs.bioconjchem.6b00335. Epub 2016 Jul 22. No abstract available.

PMID:
27447785
14.

Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.

Ravenscroft N, Haeuptle MA, Kowarik M, Fernandez FS, Carranza P, Brunner A, Steffen M, Wetter M, Keller S, Ruch C, Wacker M.

Glycobiology. 2016 Jan;26(1):51-62. doi: 10.1093/glycob/cwv077. Epub 2015 Sep 9.

PMID:
26353918
15.

Characterization of Carbohydrate Vaccines by NMR Spectroscopy.

Berti F, Ravenscroft N.

Methods Mol Biol. 2015;1331:189-209. doi: 10.1007/978-1-4939-2874-3_12.

PMID:
26169742
16.

Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella paratyphi A and used for vaccine preparation.

Ravenscroft N, Cescutti P, Gavini M, Stefanetti G, MacLennan CA, Martin LB, Micoli F.

Carbohydr Res. 2015 Mar 2;404:108-16. doi: 10.1016/j.carres.2014.12.002. Epub 2014 Dec 20.

17.

Capsular polysaccharide conformations in pneumococcal serotypes 19F and 19A.

Kuttel MM, Jackson GE, Mafata M, Ravenscroft N.

Carbohydr Res. 2015 Apr 10;406:27-33. doi: 10.1016/j.carres.2014.12.013. Epub 2015 Jan 14.

PMID:
25658063
18.

Comparative simulation of pneumococcal serogroup 19 polysaccharide repeating units with two carbohydrate force fields.

Kuttel M, Gordon M, Ravenscroft N.

Carbohydr Res. 2014 May 22;390:20-7. doi: 10.1016/j.carres.2014.02.026. Epub 2014 Mar 11.

PMID:
24681444
19.

Complete structural elucidation of an oxidized polysialic acid drug intermediate by nuclear magnetic resonance spectroscopy.

Ray GJ, Ravenscroft N, Siekmann J, Zhang Z, Sanders P, Shaligram U, Szabo CM, Kosma P.

Bioconjug Chem. 2014 Apr 16;25(4):665-76. doi: 10.1021/bc400456g. Epub 2014 Mar 28. Erratum in: Bioconjug Chem. 2016 Aug 17;27(8):1958.

PMID:
24679150
20.

Structural analysis of O-polysaccharide chains extracted from different Salmonella Typhimurium strains.

Micoli F, Ravenscroft N, Cescutti P, Stefanetti G, Londero S, Rondini S, Maclennan CA.

Carbohydr Res. 2014 Feb 19;385:1-8. doi: 10.1016/j.carres.2013.12.003. Epub 2013 Dec 11.

PMID:
24384528
21.

Malic acid supplementation increases urinary citrate excretion and urinary pH: implications for the potential treatment of calcium oxalate stone disease.

Rodgers AL, Webber D, de Charmoy R, Jackson GE, Ravenscroft N.

J Endourol. 2014 Feb;28(2):229-36. doi: 10.1089/end.2013.0477. Epub 2013 Nov 9.

PMID:
24059642
22.

Intestinal permeability in subjects from two different race groups with diverse stone-risk profiles.

Theka T, Rodgers A, Ravenscroft N, Lewandowski S.

Urolithiasis. 2013 Apr;41(2):111-7. doi: 10.1007/s00240-013-0543-1. Epub 2013 Jan 22.

PMID:
23503872
23.

Conformational properties of two exopolysaccharides produced by Inquilinus limosus, a cystic fibrosis lung pathogen.

Kuttel M, Ravenscroft N, Foschiatti M, Cescutti P, Rizzo R.

Carbohydr Res. 2012 Mar 1;350:40-8. doi: 10.1016/j.carres.2011.12.025. Epub 2012 Jan 3.

PMID:
22261278
24.

Experimental design to optimize an Haemophilus influenzae type b conjugate vaccine made with hydrazide-derivatized tetanus toxoid.

Laferriere C, Ravenscroft N, Wilson S, Combrink J, Gordon L, Petre J.

Glycoconj J. 2011 Oct;28(7):463-72. doi: 10.1007/s10719-011-9344-3. Epub 2011 Aug 19.

PMID:
21850577
25.

Bioanalysis of meningococcal vaccines.

Ravenscroft N, Wheeler JX, Jones C.

Bioanalysis. 2010 Feb;2(2):343-61. doi: 10.4155/bio.09.181. Review.

PMID:
21083312
26.

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.

Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S.

Vaccine. 2009 Jun 24;27 Suppl 2:B13-9. doi: 10.1016/j.vaccine.2009.04.062. Epub 2009 May 27. Review.

PMID:
19477559
27.

Structural analysis of fructans from Agave americana grown in South Africa for spirit production.

Ravenscroft N, Cescutti P, Hearshaw MA, Ramsout R, Rizzo R, Timme EM.

J Agric Food Chem. 2009 May 27;57(10):3995-4003. doi: 10.1021/jf8039389. Epub 2009 Apr 6.

PMID:
19348427
28.

Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A.

Foschiatti M, Hearshaw M, Cescutti P, Ravenscroft N, Rizzo R.

Carbohydr Res. 2009 May 12;344(7):940-3. doi: 10.1016/j.carres.2009.02.027. Epub 2009 Mar 4.

PMID:
19306991
29.

Synthesis of structures corresponding to the capsular polysaccharide of Neisseria meningitidis group A.

Slättegård R, Teodorovic P, Kinfe HH, Ravenscroft N, Gammon DW, Oscarson S.

Org Biomol Chem. 2005 Oct 21;3(20):3782-7. Epub 2005 Sep 13.

PMID:
16211114
30.

Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135.

Bardotti A, Averani G, Berti F, Berti S, Galli C, Giannini S, Fabbri B, Proietti D, Ravenscroft N, Ricci S.

Vaccine. 2005 Mar 14;23(16):1887-99.

PMID:
15734061
33.

Physicochemical characterisation of the oligosaccharide component of vaccines.

Ravenscroft N, D'Ascenzi S, Proietti D, Norelli F, Costantino P.

Dev Biol (Basel). 2000;103:35-47.

PMID:
11214252
34.

Physicochemical characterisation of the pertussis vaccine.

Ceccarini C, Contorni M, Costantino P, D'Ascenzi S, Gallo E, Maffei M, Mannucci D, Marsili I, Magagnoli C, Peppoloni S, Rappuoli R, Ravenscroft N, Ricci S.

Dev Biol (Basel). 2000;103:175-88.

PMID:
11214235
35.

Structure of the sialic acid-containing O-specific polysaccharide from Salmonella enterica serovar Toucra O48 lipopolysaccharide.

Gamian A, Jones C, Lipiński T, Korzeniowska-Kowal A, Ravenscroft N.

Eur J Biochem. 2000 Jun;267(11):3160-7.

36.
37.

Glycoconjugate vaccines.

Ravenscroft N, Jones C.

Curr Opin Drug Discov Devel. 2000 Mar;3(2):222-31.

PMID:
19649853
38.

Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines.

Ravenscroft N, Averani G, Bartoloni A, Berti S, Bigio M, Carinci V, Costantino P, D'Ascenzi S, Giannozzi A, Norelli F, Pennatini C, Proietti D, Ceccarini C, Cescutti P.

Vaccine. 1999 Jul 16;17(22):2802-16.

PMID:
10438050
39.

Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines.

Costantino P, Norelli F, Giannozzi A, D'Ascenzi S, Bartoloni A, Kaur S, Tang D, Seid R, Viti S, Paffetti R, Bigio M, Pennatini C, Averani G, Guarnieri V, Gallo E, Ravenscroft N, Lazzeroni C, Rappuoli R, Ceccarini C.

Vaccine. 1999 Mar 5;17(9-10):1251-63.

PMID:
10195638
40.

Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid.

Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe GR.

J Immunol. 1998 May 15;160(10):5028-36.

41.

Structural elucidation of the biological repeating unit of O-specific polysaccharide from Citrobacter serotype O41.

Ravenscroft N, Dabrowski J, Romanowska E.

Eur J Biochem. 1995 Apr 1;229(1):299-307.

42.
43.
44.
45.
46.
47.
48.
49.

Bacteriophage-associated lyase activity against Klebsiella serotype K64 capsular polysaccharide.

Ravenscroft N, Stephen AM, Merrifield EH.

Carbohydr Res. 1987 Sep 15;167:257-67.

PMID:
3690571
50.

Characterization, Biosynthesis, and Regulation of Granulose in Clostridium acetobutylicum.

Reysenbach AL, Ravenscroft N, Long S, Jones DT, Woods DR.

Appl Environ Microbiol. 1986 Jul;52(1):185-90.

Supplemental Content

Loading ...
Support Center